Companies: 49,246 Total Market Cap: 132591774254860.43

Illumina

NASDAQ: ILMN
Healthcare Diagnostics & Research
Rank #1466
Market Cap 13.13 B
Volume 2.38 M
Price 82.95
Change (%) 0.80%
Country or region United States United States

Illumina's latest marketcap:

13.13 B

As of 05/20/2025, Illumina's market capitalization has reached $13.13 B. According to our data, Illumina is the 1466th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 13.13 B
Revenue (ttm) 4.34 B
Net Income (ttm) -966,000,000
Shares Out 158.30 M
EPS (ttm) -6.08
Forward PE 19.15
Ex-Dividend Date 06/25/2024
Earnings Date 05/08/2025
Market Cap Chart
Data Updated: 05/20/2025

Illumina's yearly market capitalization.

Illumina has seen its market value grow from $512.90 M to $13.13 B since 2000, representing a total increase of 2,460.15% and an annual compound growth rate (CAGR) of 14.22%.
Date Market Cap Change (%)
05/20/2025 $13.13 B -43.41%
12/31/2024 $21.19 B -4.15%
12/29/2023 $22.11 B -30.48%
12/30/2022 $31.81 B -46.51%
12/31/2021 $59.46 B 10.08%
12/31/2020 $54.02 B 10.77%
12/31/2019 $48.77 B 10.61%
12/31/2018 $44.09 B 38.21%
12/29/2017 $31.90 B 69.6%
12/30/2016 $18.81 B -33.07%
12/31/2015 $28.10 B 7.21%
12/31/2014 $26.21 B 87.51%
12/31/2013 $13.98 B 104.45%
12/31/2012 $6.84 B 84.71%
12/30/2011 $3.70 B -53.27%
12/31/2010 $7.92 B 106.38%
12/31/2009 $3.84 B 19.06%
12/31/2008 $3.22 B -0.56%
12/31/2007 $3.24 B 77.31%
12/29/2006 $1.83 B 215.1%
12/30/2005 $580.20 M 60.72%
12/31/2004 $361 M 55.87%
12/31/2003 $231.60 M 111.51%
12/31/2002 $109.50 M -71.1%
12/31/2001 $378.90 M -26.13%
12/29/2000 $512.90 M

Company Profile

About Illumina, Inc.

Illumina, Inc. is a leading provider of sequencing- and array-based solutions for genetic and genomic analysis, serving customers across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Products & Services

  • Sequencing & Array Instruments: Includes reagents, flow cells, and library preparation tools.
  • Whole-Genome Sequencing Kits: Designed to sequence entire genomes of varying sizes and complexity.
  • Targeted Resequencing Kits: Focus on exomes, specific genes, RNA, and other genomic regions of interest.
  • Support Services: Whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support.

Customer Base

The company serves a diverse range of clients, including:

  • Genomic research centers & academic institutions
  • Government laboratories & hospitals
  • Pharmaceutical & biotechnology firms
  • Commercial molecular diagnostic laboratories
  • Consumer genomics companies

Distribution & Operations

Illumina markets its products directly to customers and through life-science distributors. Founded in 1998, the company is headquartered in San Diego, California.

Frequently Asked Questions

As of 05/20/2025, Illumina (including the parent company, if applicable) has an estimated market capitalization of $13.13 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Illumina global market capitalization ranking is approximately 1466 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region United States
Founded 1998
IPO Date 07/28/2000
Employees 10,370
CEO Jacob Thaysen
Sector Healthcare
Industry Diagnostics & Research
Address 5200 Illumina Way
San Diego, California 92122
United States
Website https://www.illumina.com
People Also Watch
TMO
413.68 0.80%
Danaher
196.41 0.80%
Lonza Group AG
680.77 0.80%
IDXX
521.68 0.80%